news
Antidepressant could slow Parkinson’s disease
Nortriptyline, which has been used to treat depression has been found to stop the growth of abnormal proteins on the brain...
List view / Grid view
Parkinson's disease
news
Asthma medicine halves risk of Parkinson’s
Researchers have found that asthma medicine can halve a patient's risk of developing Parkinson's disease...
news
Metformin may help in Parkinson’s disease
Researchers have found that a diabetes drug may help in certain types of Parkinson’s disease...
news
New drug may slow progression of Parkinson’s disease
A preclinical model of Parkinson's disease was employed to compare the effects of the dopamine agonist ropinirole to a new drug...
news
NICE publishes new Parkinson’s clinical guidance
Parkinson’s disease is one of the most common neurological conditions, affecting an estimated 130,000 people in the UK, with an annual incidence of around 15-20 per 100,000. It mainly affects people aged 50 or over.
news
Motor neurone disease onset delayed by AI-discovered drug
25 May 2017 | By Niamh Marriott, Junior Editor
The study assessed the efficacy of a drug candidate proposed by BenevolentAI’s artificial Intelligence technology for Motor Neuron Disease (MND)...
news
Amarantus forms Elto Pharma for CNS disorders and MANF Therapeutics for ophthalmology
18 April 2017 | By Niamh Marriott, Junior Editor
Amarantus Bioscience has formed a wholly-owned subsidiary named Elto Pharma for the purpose of creating investment vehicles focused exclusively on the further development of Eltoprazine, Amarantus' mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
news
Success for Renown’s Phase I study to treat “OFF” episodes in Parkinson’s patients
22 March 2017 | By Niamh Marriott, Junior Editor
The study intended to compare the plasma concentrations of sub-lingual apomorphine spray against the currently approved formulation...
news
Prothena’s Phase 1b Parkinson’s disease study showed robust antibody CNS penetration
11 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Prothena’s Phase 1b multiple ascending dose study of PRX002 trial found an acceptable safety and tolerability profile in patients with Parkinson’s disease...
news
Prexton successfully completes phase 1 Parkinson’s disease trial
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally...
news
Biomarker breakthrough could improve Parkinson’s treatment
16 August 2016 | By University of Florida
Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new experimental treatments to slow or stop the disease’s progression...
news
Collaboration to explore nilotinib as a potential treatment for Parkinson’s
13 July 2016 | By Victoria White, Digital Content Producer
Preclinical studies have shown that cancer drug nilotinib may protect neuronal cells from Parkinson's pathology by inhibiting the activity of c-Abl...
news
Parkinson’s disease therapy safinamide launches in the UK
23 May 2016 | By Victoria White, Digital Content Producer
Commenting on the launch, Maurizio Castorina, CEO of Zambon, said safinamide offers PD patients "a novel therapeutic option"...
news
FDA approves Nuplazid to treat hallucinations in Parkinson’s disease
3 May 2016 | By Victoria White, Digital Content Producer
The FDA has approved Acadia’s Nuplazid, the first drug approved to treat hallucinations and delusions experienced by some people with Parkinson’s disease...
news
Parkinson’s disease market to hit $3.2 billion by 2021
25 February 2016 | By Victoria White
GBI Research states that Parkinson’s disease market growth will occur despite the patent expiries of several key products during the forecast period...
